Company Profile
Fortress Biotech Stock Price, News & Analysis
- Ticker:
- FBIO
- Exchange:
- NASDAQ
- Sector:
- Biopharma
- Location:
- United States
Stock performance
2.79 USD (+2.57%)
Close
Last updated: August 5, 2026
88M USD
Market cap
Why the stock is moving
Following the latest company update, “Journey Medical Corporation to Announce Second Quarter 2026 Financial Results on August 12, 2026”, FBIO closed up 2.57% at $2.79 on Aug 5, 2026. The move occurred in the trading session associated with this earnings update.
Company overview
Multi-Asset Biopharmaceutical Holding Company
Fortress Biotech creates value by acquiring, forming, and advancing biopharmaceutical businesses and assets. Its portfolio includes commercial prescription products, development-stage programs, controlled subsidiaries, and minority investments across oncology, dermatology, and rare diseases.
Decentralized Company-Building Model
Fortress frequently places individual assets within focused subsidiaries that can raise capital, form partnerships, or pursue strategic transactions independently. The parent company retains value through equity ownership, royalties, milestones, and other contractual economics.
Rare Disease and Commercial Assets
Subsidiary Cyprium obtained FDA approval for ZYCUBO in Menkes disease and monetized the associated Rare Pediatric Disease Priority Review Voucher. Following Sun Pharma’s acquisition of Checkpoint, Fortress retains long-term royalty exposure to UNLOXCYT.
Multiple Monetization Pathways
Fortress can realize value through commercial product revenue, subsidiary transactions, priority review vouchers, royalties, milestone payments, and retained equity interests. This structure means portfolio value may be created through regulatory success or strategic transactions at individual subsidiaries.
Partnership-Sourced Pipeline
Fortress sources programs through collaborations with organizations including AstraZeneca, City of Hope, Nationwide Children’s Hospital, Columbia University, Dana-Farber, and Sentynl. Avenue’s acquisition of ATX-04 from Duke University adds a clinically validated program in Pompe disease.
Future catalysts
AstraZeneca has submitted regulatory applications for anselamimab in the European Union and Japan, and future regional approvals could trigger milestones for Fortress.
A potential U.S. approval milestone for anselamimab remains a defined regulatory event within the Fortress portfolio.
Recent news
- 01
Journey Medical Corporation to Announce Second Quarter 2026 Financial Results on August 12, 2026
Source: Fortress Biotech
- 02
- 03
Journey Medical Corporation to Participate in A.G.P.’s Annual Virtual Healthcare Conference
Source: Fortress Biotech
- 04
Fortress Biotech to Participate in A.G.P.’s Annual Virtual Healthcare Conference
Source: Fortress Biotech
- 05
Fortress Biotech Reports First Quarter 2026 Financial Results and Recent Corporate Highlights
Source: Fortress Biotech
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of Fortress Biotech (FBIO)?
Fortress Biotech (FBIO) most recently closed at 2.79 USD, a +2.57% move versus the previous session.
What is the market cap of Fortress Biotech (FBIO)?
Fortress Biotech currently has a market capitalization of 88M USD on BioPharmSignal.
What does Fortress Biotech do?
Multi-Asset Biopharmaceutical Holding Company Fortress Biotech creates value by acquiring, forming, and advancing biopharmaceutical businesses and assets. Its portfolio includes commercial prescription products, development-stage programs, controlled subsidiaries, and minority investments across oncology, dermatology, and rare diseases. Decentralized...
On which exchange is FBIO stock listed?
Fortress Biotech (FBIO) is associated with NASDAQ, United States, Biopharma.
What is ATX-04?
Avenue’s acquisition of ATX-04 from Duke University adds a clinically validated program in Pompe disease.
Which conditions is Fortress Biotech targeting with ATX-04?
Fortress Biotech is associated with oncology, rare disease, dermatology based on its company overview and current catalyst commentary.
How does Fortress Biotech describe recent progress with ATX-04?
AstraZeneca has submitted regulatory applications for anselamimab in the European Union and Japan, and future regional approvals could trigger milestones for Fortress. A potential U.S. approval milestone for anselamimab remains a defined regulatory event within the Fortress portfolio.
What is anselamimab?
AstraZeneca has submitted regulatory applications for anselamimab in the European Union and Japan, and future regional approvals could trigger milestones for Fortress.